Researchers from the Biomedical Data Science Laboratory (BDSLab) at the ITACA Institute of the Universitat Politècnica de ...

Though it may be what your mind runs to when you experience a weird neurological symptom, brain tumors are incredibly rare, affecting less than 1% of Americans. Knowing the possible symptoms of a ...

Claude AI from Anthropic has been defining how AI advances for real use cases. Claude Code, an AI-coding and programming partner from Anthropic, is a great tool for writing code and fixing bugs. You ...

The oldest brother of an 11-year-old U.S. citizen girl whose treatment for a rare brain tumor was interrupted when her parents were deported to Mexico is attending the State of the Union address ...

A closely watched clinical trial in Britain that screened blood for early detection of cancer did not show a reduction in diagnoses at later stages of the disease. By Rebecca Robbins and Gina Kolata A ...

Free AI tools Goose and Qwen3-coder may replace a pricey Claude Code plan. Setup is straightforward but requires a powerful local machine. Early tests show promise, though issues remain with accuracy ...

Becca Valle didn't understand why she kept having aching headaches. She was happy at a new job. She was living with her boyfriend and happy to be near her family. She had recently checked a major item ...

Goose acts as the agent that plans, iterates, and applies changes. Ollama is the local runtime that hosts the model. Qwen3-coder is the coding-focused LLM that generates results. If you've been ...

A central nervous system (CNS) tumor has prompted the FDA to place clinical holds on two Regenxbio gene therapies, including a candidate that is less than two weeks away from an approval decision.

Low-grade brain tumors known as IDH-mutant gliomas CNS WHO grade 2 are life-threatening in spite of their slow growth. Neurosurgeons across the globe are faced with the question as to striking the ...

New research has discovered that a neural circuit may explain procrastination. Scientists were able to disrupt this connection using a drug. The study, led by Ken-ichi Amemori, a neuroscientist at ...